Pure Global
NCT05934032

National Network Genomic Medicine Lung Cancer, Germany

Registry of the National Network Genomic Medicine Lung Cancer (nNGM), Linking Data on Molecular Diagnostics, Clinical Characteristics, Treatment Patterns and Outcomes of Subjects With Non-Small Cell Lung Cancer in Germany
Prof. Dr. Juergen Wolf·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Carcinoma, Non-Small-Cell Lung
Drug/Device/Intervention
observational, non-interventional
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Prof. Dr. Juergen Wolf
Funder
University of Cologne
Location
Cologne, Germany
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2018
End date
Dec 31, 2030
Enrollment
30000 participants
Primary outcome

molecular testing,treatment patterns,overall survival,time to next treatment,progression free survival

Summary

Registry of the national Network Genomic Medicine Lung Cancer (nNGM), linking data on
 molecular diagnostics, clinical characteristics, treatment patterns and outcomes of subjects
 with non-small cell lung cancer (NSCLC) from 23 specialized cancer centres and more than 400
 general hospitals and oncological practices in Germany

ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05934032
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05934032 through Pure Global AI's free database. This phase not specified trial is sponsored by Prof. Dr. Juergen Wolf and is currently Recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 30000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.